Shanghai Zeideman Pharmaceutical Technology

Thederma focuses on the research and development of innovative drugs targeting immune-mediated diseases, particularly in the fields of central nervous system (CNS), facial features, respiratory, and skin diseases. The company operates in the biopharmaceutical market, serving clinicians and patients with unmet clinical needs. Thederma's business model revolves around the discovery and development of small molecule drugs, leveraging a unique and highly differentiated product portfolio. The company generates revenue through the commercialization of these innovative drugs, aiming to provide better treatment options for clinicians and improve patient outcomes. The management team boasts extensive experience in drug R&D, technology, capital, and industry, ensuring efficient and rapid medical transformation and marketing of their products.

Keywords: immune-mediated diseases, CNS, respiratory, skin conditions, small molecule drugs, biopharmaceutical, innovative drugs, clinical needs, R&D, commercialization, treatment options.